Armenia grants first-ever approvals for Agenus cancer drug combination

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Armenia grants first-ever approvals for Agenus cancer drug combination

Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer

October 8, 2026 7:30 AM EDT

Botvymo® (botensilimab) and Evamplix® (balstilimab) receive separate approvals for use in combination Armenia is the first country to approve marketing authorization of BOT+BAL, following a rigorous review of quality, nonclinical, clinical and pharmacovigilance data Approvals supported by clinical evidence published in peer-reviewed journals and presented at major oncology congresses, including two-year Phase 1b survival findings and randomized Phase 2 data in MSS metastatic colorectal cancer without active liver metastases Agenus will evaluate the potential for approvals in other Eurasian Economic Union countries that support this regulatory... More